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Abstract
Background: Sewage workers provide an essential service in the protection of public and
environmental health. However, they are exposed to varied mixtures of chemicals; some are
known or suspected to be genotoxics or carcinogens. Thus, trying to relate adverse outcomes to
single toxicant is inappropriate. We aim to investigate if sewage workers are at increased
carcinogenic risk as evaluated by biomarkers of exposure and early biological effects.
Methods/design: This cross sectional study will compare exposed sewage workers to non-
exposed office workers. Both are voluntaries from Paris municipality, males, aged (20–60) years,
non-smokers since at least six months, with no history of chronic or recent illness, and have similar
socioeconomic status. After at least 3 days of consecutive work, blood sample and a 24-hour urine
will be collected. A caffeine test will be performed, by administering coffee and collecting urines
three hours after. Subjects will fill in self-administered questionnaires; one covering the professional
and lifestyle habits while the a second one is alimentary. The blood sample will be used to assess
DNA adducts in peripheral lymphocytes. The 24-hour urine to assess urinary 8-oxo-7, 8-dihydro-
2'-deoxy-Guanosine (8-oxo-dG), and the in vitro genotoxicity tests (comet and micronucleus)
using HeLa S3 or HepG2 cells. In parallel, occupational air sampling will be conducted for some
Polycyclic Aromatic Hydrocarbons and Volatile Organic Compounds. A weekly sampling
chronology at the offices of occupational medicine in Paris city during the regular medical visits will
be followed. This protocol has been accepted by the French Est III Ethical Comitee with the number
2007-A00685-48.
Discussion: Biomarkers of exposure and of early biological effects may help overcome the
limitations of environmental exposure assessment in very complex occupational or environmental
settings.
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Sewage workers provide an essential service in the protec-
tion of public and environmental health. In large cities,
sewage is composed of organic residues but also incorpo-
rate a wide variety of chemicals produced by roadways
scrubbing by rain, water from office and industrial facili-
ties, domestic activities (remainders of painting, drugs,
pesticides used indoor, etc). As a result of their contact
with wastes, sewage workers are exposed to complex mix-
tures of toxicants including pathogens, heavy metals,
chlorinated organic solvents like chloroform, dichlo-
roethane, perchloroethanol, other solvents (benzene, tol-
uene), aldehydes, nitrosamines, pesticides, dyes,
polychlorobiphenyls, and polycyclic aromatic hydrocar-
bons (PAH) [1-3]. Many of these compounds are known
or suspected to be genotoxics and/or carcinogens [4-6],
which suggests that those workers may be subject to ele-
vated risk of cancer.
Previous studies have indicated an increase in the inci-
dence of cancer among sewage workers [7-10]. Analyses
on specific cancer sites have reported excess numbers of
laryngeal, primary liver cancer [8,10], cancer of the pros-
tate gland, nose and nasal sinuses cancers, stomach [9],
central nervous system [11], and bladder cancers [12].
However, these data exhibit conflicting results [8,9]. A
more recent mortality study among the sewage workers of
Paris published in 2006 assessed their cause-specific mor-
tality from 1970 until 1999 [7]. A slight but significant
excess in mortality was found (SMR = 1.25, 95% CI; 1.15–
1.36) in particular from cancer mortality (SMR = 1.37,
95% CI; 1.20–1.56), with a suggested excess for oesopha-
gus, liver, pleura and the brain cancers albeit not signifi-
cant. However, this study didn't measure personal or
workplace exposures; it used only qualitative information
gathered by a questionnaire and the computerized register
of the employees.
As exposure of sewage workers implies contact with mul-
tiple potent genotoxics at varying levels (by concentra-
tion, time and location) and routes of exposure (by
inhalation, dermal and ingestion) [9], characterizing and
quantifying it are extremely difficult, and trying to relate
adverse outcomes to single toxicant is inappropriate.
However, usage of biomarkers to study the association
between exposure and early biological genotoxics effects
seems more relevant in this setting [5]. These findings may
explain that previous studies among sewage workers
exhibited conflicting results; some were biased by many
confounding factors; others relied on qualitative and/or a
questionnaire data; while others used urine or blood sam-
ples to evaluate the exposure without workplace measure-
ments. However, sewage workers might be exposed to
many agents that may interact with one another resulting
in an immeasurable amount of different chemicals.
Rather than trying to describe this immense array of expo-
sures or pursuing the goal to relate the biological health
outcomes to specific compound, it might be more reason-
able to look for unspecific early effects. Further, changes in
the composition of the sewage system over-time may
affect the level and character of worker's exposure longitu-
dinally. Thus, assessment of genotoxics at only one point
in time may not represent long term occurrence of these
substances in the body [13]. However, workplace environ-
ment sampling at various locations over-time when the
biological specimens were taken might be more represent-
able and would further support the link between occupa-
tional sewage exposure and the appearance of genotoxics
in both sample types (urine and blood).
In order to precise/assess such exposures to genotoxics/
carcinogens compounds, urine genotoxicity has been
widely used as a noninvasive method to evaluate recent
exposure among populations exposed to environmental
and/or workplace-related complex mixtures of chemicals
[14-16]. In Vitro comet [14] and micronucleus [17] assays
are among the most widely-used biomarkers of urine gen-
otoxicity for monitoring the risk of DNA damage that
stems from occupational and environmental exposures to
genotoxics. Comet assay is a sensitive technique, can
detect DNA damage in terms of double and single-strand
breaks, and alkaline-labile sites [18,19]. Micronucleus test
is a reliable biomarker of irregularity of genetic material
due to non-specific genotoxic exposure [20,21].
Of the complex mixtures to which sewage workers are
exposed, are PAHs and other genotoxic chemicals that are
metabolized by and induce the expression of cytochrome
P450 enzymes (e.g. CYP1A2) [22-24]. The CYP1A2
enzyme is involved in the metabolic activation of a wide
range of chemicals and carcinogens like PAHs and aro-
matic amines [23,24]. Its activity has been shown to be
increased by smoking, ingestion of charbroiled meat, cru-
ciferous vegetables, PAHs and PCBs exposures [23,25-28].
The catalyzed metabolism by CYP1A2 can generate ROS
which might lead to oxidative DNA damage [22,29,30].
This damage has been associated with an increased risk of
cancer generally ascribed to DNA adducts [22,31]. Thus,
measurement of CYP1A2 activity in vivo may be an
important tool to assess the exposure to chemical carcin-
ogens and cancer risk. PAHs related DNA-adducts meas-
ured by 32P- postlabeling technique is frequently
described as the biomarker of choice [32-34]. Oxidative
DNA damage may be also important in carcinogenesis
since the DNA base lesions, such as 8-oxodG, are abun-
dant and highly mutagenic [35,36]. However, DNA repair
via nucleotide and base excision processes leads to elimi-
nation and excretion of 8-oxodG in urine quantitatively
without metabolism [37-40]. Urinary excretion of 8-
oxodG is the most widely used noninvasive urinaryPage 2 of 10
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urine has been proposed to assess whole-body oxidative
DNA damage [41,42].
The CYP1A2 was shown to be responsible for the 3-
demethylation of caffeine, which is the initial major step
in the biotransformation of caffeine in human's body
[43]. Urinary metabolites of dietary caffeine is the most
noninvasively-used method in the assessment of CYP1A2
activity [44-46]. Recent studies have demonstrated that
the polymorphism of CYP1A2 could be critical in investi-
gating the induction of the enzyme [47]. The -163C>A
(allele CYP1A2*F) polymorphism has been associated
with higher enzyme inducibility by smoking [48]. Even if
the clinical relevance of this polymorphism remains con-
troversial [47], it is necessary to assess it for a good inter-
pretation of the caffeine metabolism data.
This project is interested in an association of simple, early
and non-invasive biomarkers intended to highlight expo-
sure to cocktails of undefined toxic substances having gen-
otoxic properties. We propose to carry out a cross
sectional study comparing a particularly exposed category
of workers to multiple professional pollutants (Parisians
sewage workers) with a non-exposed professional cate-
gory workers (municipality office workers) by using
biomarkers of exposure and early biological effects. The
biomarkers dedicated for this study are; the comet and
micronucleus tests, which seek the presence of genotoxics
in the urine. A second group of biomarkers highlights
early effects of these substances; the caffeine test, relevant
in the event of exposure to PAHs [49], DNA-adducts in the
lymphocytes, a biomarker of early effect indicating the
exposure to gentoxics, and urinary 8-oxo-dG, a biomarker
of early effect, corresponding to DNA oxidative stress [50].
Our primary objective is to study if the exposed present an
increased risk of genotoxic lesions, compared to the non-
exposed. The secondary objective is to evaluate the early
effects of an exposure to complex genotoxic agents. To
achieve these objectives we will; (1) analyze the urine for
DNA damage and genotoxicity (using in vitro comet and
micronucleus assays and analysis of oxidative stress
through 24 h urinary 8-oxodG), (2) analyze peripheral
blood lymphocytes for DNA-adducts by 32P-post labelling
technique, (3) assess personal exposure to PAHs and
VOCs in the workplace environment, and (4) evaluate the
PAHs exposure through assessment of CYP1A2 activity by
urinary metabolites of dietary caffeine.
The study hypothesis is that exposure of the sewage work-
ers to multiple genotoxics leads to an increase in certain
biomarkers of exposure and other biomarkers of early bio-
logical effects. The validation of our hypothesis through
these biomarkers, would allow the estimation of the total
personal exposure to complex mixture of toxic chemicals
from different exposure pathways (lungs, skin, and GIT),
and different sources (air, diet, lifestyle or occupation),
whereas the traditional epidemiological studies don't. Fig-
ure 1 presents the theoretical-overview of development
from exposure to disease and the study assessment
biomarkers.
Methods/Design
Study design, population and setting
This cross sectional study will compare an exposed popu-
lation (under-ground sewage workers) to a control group
(office workers). Both groups are from Paris municipality
workers and selected among occupational categories with
similar socio-economic status. Participation will be vol-
untary. Subjects will be current nonsmokers since at least
6 months, aged (20–60) years old, being employed dur-
ing at least the same period, have no history of chronic or
recent illness (diabetes, influenza for example) and are
not taking any medication (omeprazole for instance) that
could interfere with the study results. As sewage workers
are mostly males, the study population will be only of
males. The study will be conducted in the framework of
regular occupational medical visits. All interviews and pri-
mary procedures will be taken place at the offices of occu-
pational medicine in Paris city.
Ethical consideration
The study protocol was approved by the local ethical com-
mittees (CPP, N°2007-A00685-48). All participants will
be given an explanation of the nature of the study, and a
signed informed consent will be obtained.
Sampling chronology
Table 1 shows the weekly sampling chronology of the
study participants. Briefly, controls will be frequency-
matched for age with sewage workers with a 1 to 1 ratio.
After at least three consecutive days of work a 24 h urinary
sample will be collected from all participants (starting at
9:00 a.m). Subjects will receive a urine collecting bottle
and written/oral information describing urine collection.
After given their urine samples at 9:00 a.m of the next day
(Friday), the exposed will undergo medical examination
by occupational health physicians. Blood samples will
then be taken by nurses. Thereafter, they will receive a cup
of decaffeinated coffee added with 110 mg of caffeine.
Three hours later, a urine sample will be taken, from
which three aliquots (200 µl each) will be collected to
assess the urinary caffeine metabolites and the corre-
sponding CYP1A2 activity. During these 3 hours, subjects
will fill in two self-administered questionnaires under the
supervision of study researchers. A professional one cov-
ering socio-demographic factors, non-occupationally
exposures (especially PAHs-related: commuting means,
area of residence and indoor sources), medical history,
lifestyle (smoking history including passive smokingPage 3 of 10
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ers. The other is an alimentary questionnaire collecting
detailed-data on diet habits [51]. For the control group,
the sequence will be the same but start at 13:30 p.m.
Blood and urine samples will be processed on the same
day as described further. For the 48 h before and during
the 3 hours of the caffeine test, subjects will be asked to
avoid diets or cooking procedures known to increase
CYP1A2 activity or elicit urinary mutagenicity (e.g., cruci-
ferous vegetables; charcoal-broiled or grilled meat) or
inhibit CYP1A2 (e.g., grapefruit). They will also be asked
to refrain from consuming alcoholic drinks and beverages
containing methylxanthines and to avoid massive physi-
cal activity as it could increase DNA damage [52,53]. In
table 1 we present the morning sampling chronology for
the exposed participants.
Schematic diagram of progression from exposure to disease and the study assessment tools and biomarkersFigure 1
Schematic diagram of progression from exposure to disease and the study assessment tools and biomarkers.
Table 1: Morning sampling chronology of study participants.
*9h00 9h30 10h00-12h00 12h30 13h00 13h30
24h urine collection




Isolation and pre-treatment of lymphocytes
Biological tests (urea, creatinine)
Questionnaires
3h urine collection
Pre-treatment of 3h urine samples
Thanks Departure
*Friday of each week. In each study week, 16 participants will be sampled (8 exposed in the morning and 8 non-exposed in the corresponding 
afternoon).Page 4 of 10
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During the first part of the week, before coming to the
medical examination, the air of the working places will be
collected to be assessed for their COV or HAP content.
Sample size
Sample size was calculated for a type 2 error (α) of 5% and
power expectation of 80%. In a non-exposed population,
urines are not mutagenic in theory, and both genotoxicity
tests should be negative. Thus, if the expected prevalence
in the control is 1%, a number of 75 subjects in each
group are sufficient to highlight a prevalence of the anom-
alies of 17% in the exposed. The number of subjects nec-
essary for DNA-adducts study is similar. For urinary 8-
oxo-dG, the expected value in reference (control) popula-
tion is nearly 10.78 ± 6.6 (Mean ± SD) nmole/24h, [54].
Thus 75 subjects in each group are sufficient to detect 18%
modification of this value. For CYP1A2 activity, the uri-
nary "molar concentration ratio of 1, 7-dimethylurate
plus paraxanthine over caffeine" measured in a reference
population is 5.6 ± 1.5 (Mean ± SD) [55], so 75 subjects
in each group allow to detect a modification of 13% of
this ratio.
As describe above, 16 subjects (8 exposed and 8 non-
exposed) will be sampled Each week,. This will result in
10 weeks of sampling procedures to complete data collec-
tion according to study sample size of 75 subjects in each
group. Each corresponding afternoon, 8 non-exposed par-
ticipants will follow a similar sampling procedure.
The Parisians sewage workers are nearly 400 individuals,
recruitment will be comfortable, even after exclusion of
smokers (approximately 45%) [7].
Experimental protocol and technique
Isolation of lymphocytes
This will be carried out using Ficoll gradient centrifuga-
tion method of Bøyum [56] with few modifications
according to the study conditions. Briefly, 25 ml of freshly
obtained venous blood will be collected on anticoagulant
(EDTA) and diluted with an equal volume of standard
balanced salt solution and layered carefully over Ficoll-
Paque Plus density gradient medium, without intermix-
ing, in a centrifuge tube. After centrifuging at room tem-
perature (400 g for 30–40 min), drawing of the upper
layer by a clean Pasteur pipette will be done leaving the
lymphocytes layer undisturbed at the interface. The upper
layer which contains the plasma will be saved for later
usual clinical chemistry tests. Using a clean Pasteur pipette
the lymphocytes layer will be harvested from the interface
and transferred to a clean centrifuge tube. Then it will be
centrifuged twice (60–100 g for 10 min at 18–20°C) in a
balanced salt solution to wash the lymphocytes and
remove any remnants of platelets. The lymphocytes will
be suspended with 10% DMSO, coded, and frozen at -
80°C until extraction of DNA.
Extraction of DNA
Frozen lymphocytes suspensions will be thawed in a
37°C water bath with gentle agitation. DNA extraction
will be carried out using a standard phenol-chloroform
method including treatment with RNAses as described
elsewhere [57]. DNA purity will be checked by determina-
tion of UV spectra between 228 and 300 nm (associated
with ratio values: 1.8<A260/A280<1.95 and A260/
A230>2.3) and the DNA concentration will be deduced
from the A260, as described [58]. DNA solutions will be
divided into three portions and frozen at -80°Cin glass
vials.
Polymerase chain reaction "PCR" analysis of the CYP1A2
The polymorphism of CYP1A2 will be assessed by real-
time polymerase chain reaction and melting curve analy-
sis, as described by Casley and LeBlanc-Westwood [59].
Reactions will be carried out in 20 µL volumes containing
3.5 mM MgCl2 and 50 pg genomic DNA, using Fast Start
DNA master mix for hybridization probes from Roche
Diagnostics. All conditions will be adapted from Casley
and LeBlanc-Westwood [59].
Analysis of DNA-adducts
DNA-adducts will be analyzed by 32P-postlabelling assay
as described [60,61], using Nuclease P1 for enrichment,
with modifications from le Goff [57]. Briefly, 5 µg of DNA
will be digested, then µCi γ-32P-ATP. Separation will be
achieved on thin layer chromatography. Autoradiograms
will be obtained after exposure of Kodak Biomax film to
the TLC-plates. Each sample will be analyzed two times
and in at least two different experiments. The detection
limit will be fixed at 0.02 × 10-10, i.e. half of the lowest
quantifiable Relative Adduct Level (RAL) value. For quali-
tative analysis, the mean number of adducts per individ-
ual will be calculated.
Pre-treatment of urine samples
The volume of the 24h urine collected in sterile plastic
urine collection bottles will be measured immediately
and expressed per subject and body weight. Then, three 10
ml aliquots will be coded and frozen at -20°C for 8-
oxodG analysis. Another up to 100 ml aliquots will be
coded and frozen at -20°C for organic extraction and gen-
otoxicity tests. Both samples will be transferred to the lab-
oratory of analysis (within the same day). The
concentration of 8-oxodG in urine stored at -20°C was
shown to be constant for at least 3 years [62].
Measurement of 8-oxodG concentration in 24h urine
This will be done as described [63]. Briefly, frozen urine
samples will be thawed at 37°C for 25 min, mixed andPage 5 of 10
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formed on a C18 HPLC column (150 × 2 mm, 5 µ) pro-
tected by a C18 guard column (10 × 2 mm, 5 µ). The
mobile phase for urine samples will be 10 mM ammo-
nium formate, adjusted to pH 3.75 with formic acid and
2% acetonitrile. Electrospray will be performed in the pos-
itive ion mode. A stable isotopically marked internal
standard of 8-oxodG will be used ([15N5] 8-oxo-dG) (for
details, see reference 63).
Urine organic extracts
This will be carried on Sep-Pak C18 cartridges (Waters
Associates, Inc) adsorption chromatography as described
[64] with some modifications. Briefly, frozen urine sam-
ples will be thawed at room temperature and filtered
through Whatman filter paper No. 1. Then it will be
adjusted to pH 7 using 0.1 M NaOH. The cartridge will
firstly be washed 3 times with 3 ml of absolute methanol
and 3 ml of ultra-pure water successively before prepara-
tion of the columns. Then, the cartridge will be loaded
with urine using a glass powder funnel on the column to
facilitate the loading process. All operations will be at
room temperature. The column will then be washed 3
times with 10 ml distilled water in order to eliminate the
residual urine and histidine. The adsorbed components
will then be eluted with methanol (5 ml/100 ml urine)
into glass test tube. The eluate will be dried at 40°C under
a nitrogen stream until complete dryness. Then, the resi-
due will be dissolved in DMSO (0.4 ml/100 ml urine) and
stored at -20°C until analysis of genotoxicity tests.
Cell culture
For the two tests (comet and micronucleus) two cell lines
will be used. HeLa S3 cellular line cells will be used
(ECACC, catalog number 87110901, adherent cells of
human cervical carcinoma). Hep G2 is a perpetual adher-
ent cell line which was derived from the liver tissue of a 15
year old caucasian male with a well differentiated hepato-
cellular carcinoma (ATCC, catalog number HB-8065).
Comet assay "Single Cell Gel Electrophoresis" (SCGE)
The urine extracts kept at -20°C will be thawed and
warmed to room temperature shortly before the assay.
Comet assay will be performed basically according to Sing
et al. 1988 [65], with modifications according to Muller et
al. 2000 [66]. Briefly, the cells will be incubated with the
organic extract of urine (200 µl) during 24h (typical divi-
sion duration of these cells). Viability of cells will be
determined by trypan blue test. Microscopic slides will be
precoated with 100 µl of agarose (1%). The slides will be
gently immersed in ice-cold freshly lysis solution and will
be covered with fresh electrophoresis buffer for 20 min
and placed in a horizontal electrophoresis unit tank filled
with new fresh electrophoresis buffer. After electrophore-
sis, they will be washed with a freshly made neutralizing
buffer and stained with 50 µl ethidium bromide solution.
They will then be examined for analysis of DNA migration
under a fluorescence microscope (Olympus BX-40, Olym-
pus, Japan) using a computerized image analysis system
(Komet 5, Kinetic Imaging). Two slides will be analyzed
for each sample with fifty cells scored in each slide. Olive
tail moment will be used for analysis of results [67].
Micronucleus assay
It will be performed according to the standard protocol of
the International Workshops on Genotoxicity Test Proce-
dures [17,68,69]. Briefly, after the initial screening; well-
prepared slides will be scored using a high power magni-
fication (400–1000 folds) with both bright field and
phase-contrast microscope. Frequency of micronucleated
cells will be evaluated by the number of cells containing
one or more micronuclei (but less than 5). The induction
factor will be calculated by dividing treated values by the
control ones. Chi-square will be used for the comparisons
and when P value is < 0.05 the concentration will be con-
sidered positive.
Assessment of CYP1A2 activity by urinary caffeine 
metabolites
Subjects will be instructed to empty their bladder. Then
they will receive a cup of decaffeinated coffee added with
110 mg caffeine. Three hours later, a urine sample will be
collected and transferred to tube with 1 ml HCl, pH 3.5.
Samples will be coded and frozen at -20°C and then trans-
ferred to the laboratory of analysis (within the same day),
where it will be stored at -20°C until HPLC analysis. Caf-
feine and its metabolites will be extracted as described
[55]. Briefly, the concentrated residue will be dissolved in
800 µl of 0.05% acetic acid and filtered through a 0.45-
µm filter. Here, 100 µl of the filtrate will be injected into
HPLC column. Caffeine and its metabolites will be ana-
lyzed using an HPLC system as described elsewhere [70].
The metabolites will be identified and quantified by UV
detector with a computerized photodiode array detector
as compared with definite standards [1,7-dimethylurate
(17 U), 1,7-dimethylxantine (17X), and 1,3,7-trimethylx-
anthine (137X)]. To assess CYP1A2 activity, urinary molar
concentration ratio index [17U+ 17X/137X] will be used
as it reflects caffeine 3-demethylation activity in this phe-
notyping procedure [71,72].
Occupational air sampling
The targeted indicators will be VOCs and PAHs. They have
been selected because they are present in the confined
environments of the sewers while also emitted by auto-
mobile traffic, hence present in ambient and indoor
atmospheres, and because they are of health significance.
Since the sewage system is deprived of electricity, air sam-
pling will be carried out using battery-powered devices orPage 6 of 10
(page number not for citation purposes)
BMC Cancer 2008, 8:67 http://www.biomedcentral.com/1471-2407/8/67passive samplers. The sampling procedure will strive at
evaluating exposure near the breathing zone. However,
not to disturb the sewage workers, measurements will be
done by a companion worker (or a study personnel) who
will accompany each studied team and carry the sampling
equipment in a back bag. For the reference population
(office workers) the same type of sampling materials will
be placed in a bag located in the working area, for example
on a desk.
Measurement of Volatile Organic Compounds (VOCs)
Collection of VOCs will be carried out on thermal desorp-
tion sorbent tubes exposed during the sewage workers
worktime from Monday to Thursday and the sampler is
recapped after every exposure. Analysis will be carried out
by coupling gas chromatography and mass spectrometry.
As work in sewage system takes place in a wet environ-
ment, a sorbent tube not very sensitive to moisture will be
chosen. The list of the selected indicators will be at least
the substances measured inside residences within the
framework of the national inventory carried out by the
Observatory of Indoor Air Quality (OIAQ) in more than
560 French residences. These data were published in
November 2006 [73] and can be used as reference values.
It is probable that most of compounds found in the resi-
dences are also present in the air of the offices. The basic
list is as follows:
- Alkanes: decane, undecane
- Monocyclic aromatic hydrocarbons: benzene, toluene,
meta and para-xylenes, orthoxylene, 1, 2, 4-trimethylben-
zene, styrene
- Chlorinated hydrocarbons: trichloroethylene, tetrachlo-
roethylene, 1–4-dichlorobenzene.
The tubes used for sampling will be analyzed at the Paris
city hygiene laboratory on a chain including a thermal
desorption module on line with a chromatograph in gas
phase equipped with a capillary column and coupled to a
mass spectrometer (Quadripole). Quantitative analysis
will be carried out on the basis of ion extracts and a range
of calibration prepared by doping a lot of sorbent tubes
with various quantities of a mixture of the selected VOCs.
The first samples (2 to 3) will be devoted to the qualitative
analysis (screening) of the chromatographic profiles with
the aim to adjust the list of targeted compounds.
Measurement of Polycyclic Aromatic Hydrocarbons
They will be collected with personal air samplers allowing
the simultaneously trapping of the volatile and the partic-
ulate phases (in case of heavy loss of charge due to high
charged XAD2 resin, it will be necessary to carry out two
distinct samples, one collecting only gaseous PAHs, the
second one for particulate PAHs). The head of the sam-
plers will consist of a cassette containing a filter, to collect
particles coupled to a marketed tube filled with XAD2
resin or polyurethane foam. Air will be drawn using a con-
stant flow sampling pump at a calibrated flow-rate of 2 L/
min.
Duration of sampling will be at least equal to the daily
worktime. However, four consecutive days of cumulative
sampling may be necessary because concentrations are
expected to be low. In this case, filter will be preserved in
an aluminum sheet to avoid photochemical transforma-
tions. A first series of measurements will allow determina-
tion of the minimal duration of exposure for an
acceptable quantification limit.
Thirteen PAHs will be measured: phenanthrene, anthra-
cene, fluoranthene, pyrene, benzo(a)anthracene,
chrysene, benzo(j)fluoranthene, benzo(b)fluoranthene,
benzo(k)fluoranthene, benzo(a)pyrene, dibenzo(a,h)
anthracene, benzo(g,h,i) perylene, indeno-pyrene. PAHs
will be extracted at the laboratory by a solvent in a pressu-
rized cell, so the extracts will be concentrated in an auto-
matic evaporator. They will be analyzed by high HPLC
associated with fluorimetric detection. A binary elution
gradient consisting of water and acetonitrile will be used
to separate the different PAHs. Several couples of wave-
lengths of excitation and emission will be selected to opti-
mize the sensitivity of the response of the compounds and
to limit the chromatographic interferences. The quantita-
tive analysis will be carried out according to the response
of standard solutions that are prepared from a marketed
mixture of the selected PAHs.
Statistical analysis
For each parameter, data will be compared between the
exposed and non-exposed groups. Data will be tested for
homogeneity of variance and normality after variable
transformation if appropriate. Two-tailed Student's t-test
will be used for group and/or sample comparisons relative
to DNA-adducts level. Fisher's exact test will also be used
for comparison of DNA-adducts pattern distributions
between groups. Linear regression analysis will be used for
quantitative variables, adjusting for parameters that reflect
exposures in the questionnaires. For other parameters,
ANOVA will be performed. Correlation analysis of DNA-
adducts levels and urine genotoxicity with qualitative
parameters will be evaluated by Spearman tests. Potential
confounding factors, like age, socioeconomic or passive
smoking will be studied, mainly by evaluating their distri-
bution in both groups and by looking for possible associ-
ation with DNA-adducts levels, urine genotoxicity or
caffeine metabolism tests. The influence of confounding
factors will be determined by multiple logistic regression
after a check of normality (Kolmogorov Smirnov's test).Page 7 of 10
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Discussion
This study aims to investigate the carcinogenic risk associ-
ated with occupational exposure of sewage workers to
complex chemical mixtures. While the comet assay can
detect DNA reparable lesions or alkali-labile sites, micro-
nucleus can detect fixed mutations that persist at least one
mitotic cycle [74]. Positive results in the comet don't nec-
essarily correspond to positive results in the micronu-
cleus, especially when genotoxic exposure is small. Thus,
the combination of both assays might be more accurate
and reasonable. Urinary excretion of 8-oxodG is a repair
product of oxidative DNA damage and under the usual
steady conditions it reflects the general average risk of a
promutagenic oxidative stress in DNA of all tissues and
organs [75]. Further, DNA-adducts in peripheral lym-
phocytes is considered as a good biomarker when study-
ing the early effect of genotoxic exposures in humans
[76,77].
This study is limited by its cross sectional design where
systematic differences between exposed and non-exposed
could cause under or overestimation of the risk, as
exposed subjects may be more motivated to participate
than non-exposed. However, genotoxicity tests (urine and
lymphocytes) are not likely to be affected by the subjects'
interest to the study. Moreover, choosing office workers as
a control group may alleviate sources of strong bias such
as "healthy worker effect" and social class differences, as
both groups belong to the same socioeconomic class. Fur-
ther, urine genotoxicity is a short-term measure that
reflects exposure 24 to 72h before collection [78] and our
blood samples will be taken at rest. Airborne assessment
will assess exposure by inhalation only, thus possibly mis-
classifying exposure both quantitatively and qualitatively.
Using biomarkers of exposure and of early effects aims to
overcome this shortcoming in view to assess the risk.
Some difficulties might stem fromthe tiny amounts of
promutagens in urine and the presence of urinary histi-
dine, that leads to false positive results. Filtration and con-
centration of urine might help to solve these problems
[64]. Finally, day to day variability in laboratory proce-
dures will be calculated and estimated by analysis.
To summarize, sewage workers are exposed to multiple
chemicals from multiple pathways resulting in a compli-
cated matrix of exposure to chemicals and concentrations.
In this complex chemical exposure setting, this study com-
bines biological sampling, both in blood and urine, to
assess biomarkers of exposure and of early biological
effects. These biological indicators will be scaled with
results of workplace environment air sampling that will
be conducted in parallel. Such biomarkers of exposure
and of early biological effects may help overcome the
severe limitations of environmental exposure assessment
in very complex occupational or environmental settings.
If shown discriminating in the framework of this study
population, these non-specific biomarkers might be used
to assess the genotoxic risk in other populations also expe-
riencing complex exposures.
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